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Inclusion of artesunate in the cavity of b-cyclodextrin (b-CD) as well as its methyl and hydroxypropyl
derivatives was investigated experimentally and by molecular modeling studies. The effect of PEG on
the inclusion was also studied. A 1:1 stoichiometry was indicated by phase-solubility studies both in
the presence and absence of PEG and suggested by the mass spectrometry. The mode of inclusion was
supported by 2D NMR and results were further veriﬁed by docking studies utilizing Fast Rigid Exhaustive
Docking acronym. The thermodynamic parameters were determined for both binary and ternary
systems using solution calorimetry and were found to be best for the methyl-b-cyclodextrin (Me-b-CD)
system. However, the presence of PEG improves the complexation ability as evident from elevation in
the numerical value of the stability constant (K). Solubility and dissolution proﬁle of binary complex is
enhanced in the presence of PEG, which is approximately at par with drug Me-b-CD complexes. In vivo
studies showed 100% survivability in artesunate–Me-b-CD complexes.
& 2011 Published by Elsevier B.V.1. Introduction
Despite the fact that we live in an era of advanced technology
and innovation, infectious diseases, like malaria, continue to be one
of the greatest health challenges worldwide. The main drawbacks of
conventional malaria chemotherapy are the development of multi-
ple drug resistance and the non-speciﬁc targeting of intracellular
parasites, resulting in high dose requirements and subsequent
intolerable toxicity [1,2]. Artemisnin derivatives are one of the few
antimalarial drugs that remain effective against multidrug resistant
strains of Plasmodium falciparum malaria [3–5]. Unfortunately,
artesunate, a potent blood schizonticidal belonging to Class II of
Biopharmaceutical Classiﬁcation System, shows poor water solubi-
lity and low bioavailability following oral administration. This
causes formulation problems and limits its therapeutic applications
and bioavailability [6–8]. Various approaches such as liposomes [9]
and nanoparticles [10] have been employed to enhance its solubility
and bioavailability. However, no detailed study is reported on the
cyclodextrin complexes except one report where the authors have
reported the NMR data on artesunate–b-CD complexes [11].Elsevier B.V.
Chadha).Therefore, the present study is undertaken to utilize the CDs for
improving the physicochemical properties as well as for therapeutic
index of this poorly soluble drug. The focus of the work is to
characterize the host–guest interactions by determining the stability
constant and the other thermodynamic parameters associated with
complexation. However, high molecular weight, cost, production
capability and possible parenteral toxicity have hindered the use of
CD’s in the formulations [12]. A useful strategy to overcome these
difﬁculties is the use of the third component such as water-soluble
polymers [13–19], an emulsifying agent [20], a surfactant [21], a
hydroxyacid [22,23]. These can enhance the CD complexing ability
and result in the reduction of the above mentioned drawbacks
associated with CD complexes. Consequently, the present work is
extended by incorporating water-soluble polymer in drug–b-CD
complexes to improve the complexing abilities leading to the better
solubilizing efﬁciency by multicomponent complex formation. Out
of all the three CD’s, only b-CD is used for further studies because of
its low price, easy availability, highly suitable cavity dimensions and
the least toxicity [24]. The pharmacological activity of binary and
ternary complexes was performed to evaluate their efﬁcacy, which
has been correlated with the complexing abilities of different CDs.
The inclusion mode and stoichiometry of the reaction are supple-
mented by molecular modeling.
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2.1. Materials
Artesunate was obtained as gift sample from Ipca Laboratories
Ltd. Mumbai, India. b-CD, Me-b-CD and HP-b-CD were obtained
from Sigma Aldrich. The other analytical grade chemicals such as
sodium hydroxide, potassium hydrogen phosphate, sodium dihy-
drogen phosphate and polymers were procured from SD ﬁne
Chemicals, Chandigarh.2.2. Methods
2.2.1. Preparation of binary complexes
Artesunate with b-CD, Me-b-CD or HP-b-CD was mixed in 1:1
molar ratio by different methods as given below:
Physical mixing (PM): Physical mixtures were prepared by
simple mixing of drug with the selected CD in a mortar and to
ensure uniform mixing. The vials ﬁlled with the mixtures were
subjected to vortex mixing for 5 min.
Kneading (KN): Drug and CD’s were blended together in a
mortar with sufﬁcient water to produce a paste and was kneaded
for 90 min. The product was then dried under vacuum at 40 1C for
48 h and passed through a 150 mmmesh and stored in a glass vial
in a vacuum desiccator.
Freeze-drying method (LY): The required 1:1 stoichiometric
quantity of drug was added to an aqueous solution of the selected
CD and was agitated on a magnetic stirrer for 24 h. The resulting
solutions were frozen at (80 1C) in a deep freezer for overnight.
This was then lyophilized under 17.2 mTorr for 48 h. The samples
were transferred immediately into a vacuum desiccator and dried
over silica gel under vacuum for at least 24 h.2.2.2. Preparation of ternary cyclodextrin complexes
Ternary complexes were prepared by physical mixing, Knead-
ing, Lyophilized suspension method (Ly Susp) and Coevaporation
method.
Coevaporated (CoE) solid system method: Equimolar
amounts of artesunate and b-CD systems with 0.25% PEG were
dissolved in water. The resulting solution was evaporated on a
rotary evaporator at 60 1C to get a solid residue. The prepared
system was dried in vacuum desiccators.
Characterization: Binary and ternary inclusion complexes of
artesunate were characterized in the solid phase by DSC, PXRD,
FT-IR, mass spectrometry and in solution phase by solution
calorimetry and NMR.2.3. Equilibrium solubility studies
Phase-solubility diagrams of artesunate for both binary and
ternary systems with various CDs in phosphate buffer (pH 6.8)
were obtained according to Higuchi and Connors [25]. An excess
amount of the sample was added to 10 mL buffer or CD buffered
solutions with a concentration of w/v (2–20 mM) in 20 mL glass
vials with or without a polymer (0.25% PEG). The suspensions
were sealed and shaken in water-bath shaker (MSW-275, Macro-
scientiﬁc Works Pvt. Ltd., Delhi) at 3770.5 1C for 24 h to ensure
equilibrium. After equilibration, aliquots of the supernatant were
withdrawn, ﬁltered through 0.45 mm Millipore ﬁlter paper, and
the artesunate content was determined spectrophotometerically
at l¼240 nm (UV/vis Spectrophotometer (Perkin Elmer Lamda
15, USA). The presence of CDs did not interfere with the spectro-
photometric assay of the drug. The standard plot of artesunate
was prepared by dissolving a weighed amount of the drug inphosphate buffer pH 6.8, suitably diluted and absorbance taken at
wavelength 240 nm on a spectrophotometer.
2.4. Mass spectrometry
ESI-MS studies were performed using a Q-ToF quadruple time
of ﬂight mass spectrometer (Waters Pvt. Ltd., USA) equipped with
an electrospray source. The sample was introduced via a syringe
pump at a ﬂow rate of 5 mL/min. High ﬂow rate nitrogen gas was
employed as the nebulizing gas as well as the drying gas to aid
desolvation. The sheath gas ﬂow rate was 0.5 mL/min. After
optimization of the MS parameters, the spray voltage was set to
2.5 kV in the positive mode, and the heated metal capillary
temperature was set at 80 1C. The mass scale was calibrated using
the standard calibration procedure and compounds provided by
manufacturer.
2.5. Differential scanning calorimetry (DSC)
DSC thermograms were obtained on DSC (Q20, TA Instru-
ments-Waters LLC, USA). The calorimeter was calibrated for
temperature and heat ﬂow accuracy using the melting of pure
indium (mp 156.6 1C and DH of 25.45 J/g). The temperature range
was from 50 to 350 1C with a heating rate of 10 1C per minute.
2.6. X-ray powder diffraction
Powder diffraction patterns were recorded on an X-ray dif-
fractometer (XPERT-PRO, PANalytical, Netherlands, Holand) with
Cu as tube anode; the diffractograms were recorded under
following conditions: voltage 40 kV, 35 mA, angular range 5 and
ﬁxed divergence slit.
2.7. Fourier transform infrared spectrometry (FT-IR)
The FT-IR spectra were obtained on an FT-IR spectrometer,
Mode spectrum RXI, Perkin Elmer, England, over the range 400–
4000 cm1. Dry KBr (50 mg) was ﬁnely ground in an agate mortar
and samples of drug and their complexes (1–2 mg) were subse-
quently added and mixed gently. A manual press was used to
form the pellets.
2.8. 2D COESY, proton nuclear magnetic resonance (1H NMR)
and 13C NMR spectroscopy
1H NMR, 13C NMR and 2D COESY spectra in d6DMSO of
artesunate and inclusion complexes were recorded with a Brucker
AC 300 1C NMR spectrometer apparatus operating at 300 MHz
using tetramethylsilane as an internal standard. For 2D COESY
experiments, samples were equilibrated for at least 24 h.
2.9. Solution calorimetry study
Isoperibol solution calorimeter (ISC) (Calorimetry Science
Corporation, UTAH, USA) model 4300 was used for enthalpy of
solution measurements. The calorimeter consists of a constant
temperature bath held at 37 1C (70.005 1C) and heater assembly.
The drug was ﬁlled into batch adapter of volume 0.9 mL, sealed
on both sides with ‘O’ rings and cover glass. The batch adapter
holding the drug was inserted into the Dewar ﬂask containing
buffer (25 mL). The combined unit was then lowered in the
calorimeter bath. The glass stirrer was rotated at 100 revolu-
tions/min and was allowed to equilibrate for 90 min. The ampoule
was shattered automatically by means of a plunger and tempera-
ture change was noted. The performance of the system was
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(70.03 kJ/mol).2.10. Dissolution study
The dissolution studies of the artesunate and its binary and
ternary complexes were performed in 900 mL of phosphate buffer
(pH 6.8 using) USP [12] apparatus at pre-equilibrated temperature
3770.5 1C and at a stirring rate of 50 rpm. Drug and its inclusion
complexes containing 100 mg of drug were ﬁlled in hard gelatin
capsules. Samples were withdrawn at different intervals for a period
of 6 h and analyzed spectrophotometrically at l¼240 nm.
2.11. Molecular modeling studies
2.11.1. Computational details
The computational studies were carried out on an Intel Xeon
based system with the Linux OS (CentOS 5.4). Structure prepara-
tion, simulations and analysis were carried out with Maestro
version 9.1 (Schro¨dinger LLC, New York, NY, 2010). The docking
studies were carried out with Fast Rigid Exhaustive Docking
acronym (FRED version 2.2.5, OpenEye Scientiﬁc Software, Santa
Fe, USA) [26,27] while the Molecular Dynamics simulations
was performed using Desmond (version 2.4, DE Shaw Research,
NY, USA).2.11.2. Structure preparation
The 3D structures of b-cyclodextrin (b-CD) and artesunate
were retrieved from the Protein Data Bank [28] and PubChem
(CID 5464098). The structures were ‘cleaned’ w.r.t. geometries,
atom types and charges based on the OPLS2005 forceﬁeld in
Schro¨dinger Suite.2.11.3. Docking studies
The b-CD molecule was subsequently imported into the program
FRED-RECEPTOR (version 2.2.5) for docking. During the rigid body
docking of the guest molecule into the host, the intrinsic scoring
function Chemguass2 was utilized for identiﬁcation of the docking
solutions. From a set of 1000 solutions the best 100 were saved. On
visual assessment the best solution was subsequently taken up for
MD simulation using Desmond.2.11.4. MD simulations
Initially the complex of b-CD–artesunate was solvated with
TIP3P waters [29] to form a water shell 10 A˚ thick around the
b-CD–artesunate complex. Naþ ions were added to attain a net
charge of zero on the system. The solvated host–guest system was
simulated for a period of 5 ns with the ‘NPTrelaxprotocol’ in Desmond.
The protocol involves an initial minimization of the solvent with the
solute restrained. The minimization is followed by short MD
simulations of 12–24 ps in sequential NVT and NPT ensembles with
the Langevin thermostat and barostat [30]. The temperature was
maintained by coupling to an external 300 K bath based on the
Langevin algorithm. The pressure was isotropically restrained to
1 bar with the Langevinbarostat. High-frequency vibrations were
removed by applying the SHAKE algorithm [31] by constraining all
bonds to their equilibrium values. Initial velocities were generated
randomly from a Maxwell distribution at 300 K in accordance with
the masses assigned to the atoms. The trajectories and correspond-
ing energies were sampled every 5 ps. No constraints were applied
on the b-CD–artesunate system during the simulations, so as to
avoid introduction of any artifacts in the ligand conformation in the
binding site.2.12. In vivo studies: evaluation of pharmacological antimalarial
activity of artesunate, its binary and ternary complexes in mice
Four to ﬁve weeks old BALB/c mice (25–30 g) were procured and
maintained in the Central Animal House. They were provided with
standard pellet diet and water ad libtum. Experiments were per-
formed as per guidelines of Control and Supervision on Experiments
on Animals (CPC-SEA) Committee. The experimental protocol was
approved by the Institutional Animal Ethics Committee (A.I.E.C.).
Plasmodium berghei (NK 65) strain was used for evaluation of
antimalarial activity in vivo studies and was maintained in the mice.
All the mice belonging to control group were challenged with 106
P. berghei infected red blood cells (RBCs) intraperitonial (i/p). After
challenge mean percent parasitemia, percent activities of various
complexes of artesunate along with animal survivality were mon-
itored. Mean percent parasitemia was calculated for each group on
every alternate day up to 30 days by tail blood smear, ﬁxed in
methanol and stained in Giemsa stain by counting at least 500 cells
Mean percent parasitemia¼ infected RBCs 100=Total no: of RBCs
Animals were divided into 6 groups and each group comprised
of 6 animals (n¼6). These were treated orally with single dose
therapy (6 mg/kg of artesunate) two times a day on 1 day of post
inoculation (PI) for 7 days to monitor the efﬁcacy and potency of
prepared lyophilized binary and ternary complexes. Each animal
was treated orally with 100 mL artesunate and its various lyophi-
lized complexes.1. Control group—treated with 0.5% carboxymethyl cellulose
(CMC) suspension;2. Standard group—administered artesunate in 0.5% CMC
suspension;3. Test group 1—treated with binary As–b-CD complex in 0.5%
CMC suspension;4. Test group 2—treated with binary As–Me-b-CD complex in
0.5% CMC suspension;5. Test group 3—treated with binary As–HP-b-CD complex in 0.5%
CMC suspension and6. Test group 4—treated with ternary As–b-CD–PEG complex in
0.5% CMC suspension.
2.12.1. Statistical analysis
Data of parasitemia of animals treated with different inclusion
complexes were statistically assessed by one-way ANOVA and
Turkey’s test using Jandel sigma stat 2.0 version. Differences were
considered signiﬁcant at Po0.05.
The value of equilibrium constant (K) and enthalpy of binding
(DHo) were determined by our computer program utilizing an
iterative non-linear least square regression method to minimize
the value of
P
(DHint(exp)DHint(calc))2 where DHint(exp) is the
experimentally determined enthalpy of interaction per liter of
solution, DHint(calc) is the calculated enthalpy of interaction per
liter of solution using iterative method.3. Result and discussion
3.1. Equilibrium phase-solubility studies
The equilibrium phase-solubility study diagrams were found
to be linear characterizing their AL type nature and suggest the
formation of ﬁrst order soluble complexes for artesunate with
b-CD, HP-b-CD and Me-b-CD (Fig. 1). The increment in the
solubility of drug seems to depend upon inclusion ability of
cyclodextrin molecules with the solubilization strength increas-
ing in the order: b-CDoHP-b-CDoMe-b-CD.
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As discussed above, the study involves the use of third
component for improving the solubilizing efﬁciency as well as
to decrease the bulk of formulation. Increment in the solubility of
the drug with b-CD was measured in the presence from selected
polymers (Fig. 2). The most effective third component for the
ternary system was selected on the basis of solubilizing efﬁciency
of the corresponding drug–cyclodextrin and drug–polymer
systems. Various additives such as polyvinylpyrrolidine (PVP),
hydroxylpropyl methyl cellulose (HPMC), polyethylene glycol
(PEG) and poloxamer were used and the effect of these polymers
on the solublizing efﬁciency is shown in Fig. 2 and 0.25% PEG was
found to be the best of all the polymers. The addition of PEG
resulted in 20 times increase in solubility as compared to the
13.4-fold increase in its absence at the same concentration of
binary complex (Fig. 1). Only b-CD was used for the preparation of
ternary complexes because of its lower cost and less parental
toxicity compared to Me-b-CD and HP-b-CD. Interestingly, the
enhancement in solubility of drug in the presence b-CD and PEG
is approximately equal to that in the presence of Me-b-CD alone.
The addition of water-soluble polymers to the CD solution did notFig. 1. Phase-solubility diagram of artesunate with b-CD, Me-b-CD and HP-b-CD
as well as with b-CD in the presence of 0.25% PEG at 37 1C (As–b-CD–PEG).
Fig. 2. Selection of third component of diffchange the type of phase-solubility diagrams obtained for binary
systems (1:1 stoichiometry).
3.2. Electrospray ionization mass spectrometry (ESI-MS)
The use of ESI-MS for characterizing the stoichiometry and
strength of interactions between synthetic or biological hosts and
guests is a growing area of research [32,33]. It is clear from the
ﬁgure that peaks observed in mass spectra at m/z 1157, 1543,
1717 and 1787 correspond to the charged [b–CDþNa]þ , [Asþ
b–CDþNaþH]þ , [AsþMe-b–CDþNa]þ and [AsþHP-b–CDþNa]þ ,
respectively, indicating 1:1 stoichiometry (Fig. 3).
3.3. Differential scanning calorimetry (DSC)
Differential scanning calorimetry (DSC) provides evidence for
differences between the physical mixtures and the putative
inclusion complex. The complete disappearance of the fusion
endotherm was observed for binary lyophilized complexes indi-
cating formation of a true inclusion complex. In the physical
mixtures of drug with b-CD, Me-b-CD and HP-b-CD, the phase
transition thermal proﬁle of artesunate (140.2 1C) remained
recognizable with the reduction and the broadening of drug
fusion peak, with concomitant shift to lower temperature (Fig. 4).
Similarly, the ternary systems prepared by lyophilized suspen-
sion method showed complete absence of melting endotherm of
the drug. Whereas, the kneaded complexes as well as in coeva-
porated system exhibited the melting endotherm with reduced
intensity suggesting a weak interaction between the components
(Fig. 5).
The interesting feature of the ternary complexes is the absence
of the decomposition peak in lyophilized suspension system and
in coevaporated ternary system supporting the fact that the
inclusion of the drug has enhanced its physical stability.
3.4. X-ray powder diffraction (XRPD)
The diffraction patterns of the complexes should be clearly
distinct from that of superimposition of each component if a real
inclusion has taken place. The presence of drug characteristic
peaks with reduced intensity in physical mixtures and kneadederent additives on b-CD concentration.
Fig. 3. Mass spectra of artesunate with (a) b-CD, (b) Me-b-CD and (c) HP-b-CD.
Fig. 4. DSC thermograms of (a) artesunate, (b) As–b-CD PM, (c) As–b-CD KN,
(d) As–b-CD LY, (e) As–Me-b-CD PM, (f) As–Me-b-CD KN, (g) As–Me-b-CD LY,
(h) As–HP-b-CD PM, (i) As–HP-b-CD KN and (j) HP-b-CD LY.
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phenomenon (Fig. 6). It is no longer possible to distinguish the
characteristic peaks of the drug in the lyophilized system, which
showed a modiﬁed and hollow pattern suggesting the formation
of amorphous inclusion complex with Me-b-CD and HP-b-CD.
The ternary systems of all the formulations with b-CD showed
some diffraction 2y peaks with little intensity, which is attributed
to a crystalline nature of b-CD (Fig. 7).
3.5. Fourier transform infrared spectroscopy (FT-IR)
FT-IR spectra of the binary and ternary inclusion complexes
are quite similar to the corresponding CDs because of the
coincidental absorption of both the host and guest molecules in
the same spectral regions. However, the small shifts in character-
istic bands of drug at 1719, 1370 and 1029 cm1 undoubtedly
conﬁrm the presence of drug in all the complexes.
3.6. Proton NMR spectroscopy
Inclusion of drug protons resulted in modiﬁcation of NMR
frequencies of both the guest (artesunate) and the host (CD). A
downﬁeld shift in the cycloheptane protons l, k, j, i, m and h of drug
revealed the presence of artesunate molecule into the cyclodextrins
cavity. Insertion is favored towards the cycloheptane ring with
endoperoxide group due to its narrower dimension (2.89 A˚) as
compared to the opposite end of the drug molecule, consisting of
two cyclohexane rings (6.9 A˚) (Fig. 8). Insertion of side chain of
artesunate molecule is ruled out due to more hydrophilic nature.
A downﬁeld displacement in protons c and o indicate that these
protons are closer to the electronegative atom (oxygen) on the
exterior of the CD cavity. Two-dimensional (2D) COESY spectra were
used further to get a better insight into the geometry of the complex.
It provides the information about the spatial proximity between host
Fig. 5. DSC thermograms of artesunate with (a) b-CD–PEG PM, (b) b-CD–PEG KN, (c) b-CD–PEG CoE and (d) b-CD–PEG LY Susp.
Fig. 6. PXRD pattern of artesunate with (a) b-CD PM, (b) b-CD KN, (c) b-CD LY, (d) Me-b-CD PM, (e) Me-b-CDKN, (f) Me-b-CDLY, (g) HP-b-CDPM, (h) HP-b-CDKN and
(i) HP-b-CD LY.
R. Chadha et al. / Results in Pharma Sciences 1 (2011) 38–48 43
Fig. 7. PXRD pattern of artesunate with (a) b-CD–PEG PM, (b) b-CD–PEG KN, (c) b-CD–PEG LY Susp and (d) b-CD–PEG CoE.
Fig. 8. (a) The chemical structure of artesunate and (b) inclusion mode of drug
into cyclodextrin cavity.
Fig. 9. 1H COESY of artesunate with (a) b-CD, (b) Me-b-CD and (c) HP-b-CD.
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appearance of cross peaks (Fig. 9) between H-5 and H-3 protons of
CD and H-l, H-j and H-g protons supports our proposed inclusion
mode involving insertion of cycloheptane ring with endoperoxide
bridge (trioxane ring) deep into the cavity. No data is available for
the direct comparison of NMR studies except one work reported by
Hartell et al. In this work the authors reported that trioxane ring as
well as aromatic ring of artesunic acid is complexed with the CDs,
thus supporting our results. However, authors also suggested the
possibility of 2:1 stoichiometry whereas our studies reports 1:1
stoichiometry.
3.7. Thermodynamic parameters of inclusion complexes in the
presence or absence of PEG
Solution calorimetry is used to quantify the binding interac-
tions between the drugs with CD’s forming noncovalentcomplexes in aqueous solution and to determine the relationship
between noncovalent structure and free energy of binding includ-
ing the roles of enthalpy and entropy of association.
Stability constant and other thermodynamic parameters were
calculated by determining the enthalpy of solution of the drug in
the absence and presence of CDs as well as PEG. The molar
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mic (0.09 kJ/mol) in phosphate buffer (pH 6.8). Enhanced
exothermic behavior was exhibited by the drug in the presence
of CDs and further enhancement was observed when both CDs
and 0.25% PEG were present. This is attributed to synergetic
interaction between drug and the cyclodextrin in the presence of
PEG. The enthalpy of interaction was calculated by the following
equation:
DHintðexpÞ ¼
DsolHðCDÞDsolH
vðlÞ ð1Þ
where DHint(exp) is the enthalpy of interaction between drug and
cyclodextrin per liter of solution, DsolH and DsolH(CD) are the
enthalpies of solution of drug in buffer and in buffered aqueous
solution of cyclodextrin, respectively, v (l)¼volume of sample cell
in liters (0.025 L).Table 1
Interaction enthalpy of inclusion complexes artesunate with Me-b-CD at pH 6.8.
x2 MAs (a)
((M)104)
Mm-b-CD (b)
((M)104)
DsolH(CD)
((J)10)
DHint(exp)
(J/L)
DHint(M)
(kJ/mol)
0.902 3.26 30.49 1.80 3.47 1.03
0.851 3.92 22.35 2.17 4.09 1.56
0.801 3.79 15.22 2.09 3.63 1.91
0.754 3.68 11.29 2.04 3.36 2.25
0.688 3.25 7.15 1.79 2.36 2.27
0.606 1.97 3.03 1.09 1.14 2.28
0.515 2.87 3.05 1.59 1.38 2.33
0.458 3.63 3.07 2.01 1.52 2.28
0.397 4.71 3.09 2.61 1.70 2.18
0.315 7.08 3.26 3.92 2.20 2.13
0.259 8.88 3.10 4.92 2.50 2.09
0.202 11.94 3.07 6.62 2.78 -1.85
0.157 14.12 2.63 7.82 2.50 1.49
0.096 14.31 1.52 7.93 1.48 0.93
Fig. 10. Plot of DsolHint(M) versus mole fraction (x2) of artesunate with b-CD,
Me-b-CD, HP-b-CD and As–b-CD–PEG at pH 7.
Table 2
Thermodynamic parameters of artesunate with b-CD, Me-b-CD a
phosphate buffer, determined using solution calorimetry.
System K (M1) DHo (kJ/mo
Asþb-CD 122775.0 –9.1070
AsþHP-b-CD 185278.0 –11.0070
AsþMe-b-CD 2410710.0 –12.0270
Asþb-CDþPEG 2250716.0 –11.870Enthalpy of interaction per mole of drug and b-CD (DHint(M))
were calculated from
DHintðMÞ ¼
DHintðexpÞ
aþb ¼
DsolHðMÞðCDÞDsolHðMÞ
1þðx2=x1Þ
ð2Þ
where a and b are the initial molar concentrations of drug and
cyclodextrin, x1 and x2 are the apparent mole fractions of the drug
and cyclodextrin ignoring the concentration of other ingredients
in the buffer.
The detailed calorimetric data for artesunate and Me-b-CD are
given in Table 1.
The stoichiometry of the complex was ascertained utilizing
continuous variation method (Job’s plot) [34] by plotting (DHint(M))
versus (x2) (Fig. 10). It can be seen that the minimum occurs at
x2¼0.5, which indicates that the complex has 1:1 stoichiometry and
supports its determination by other techniques.
Similarly the enthalpy of interaction for the ternary system
was calculated by subtracting the enthalpy of solution of drug in
the presence of cyclodextrin and 0.25% PEG from that in pure
buffer (DHo(M)).
The thermodynamic constants are calculated assuming the
following equilibria:
CDþartesunate2CD:artesunate (3)
The experimentally calculated enthalpy of interaction (DHint(exp))
is proportional to the product of molar concentration of CD:arte-
sunate complex (c) in the solution at equilibrium and enthalpy of
binding per mole of drug (DHo)
DHintðexpÞ ¼DHo  c¼DHoKðacÞðbcÞ ð4Þ
The binding constant K and enthalpy of binding (DHo) for both
binary and ternary systems were computed from the experimen-
tally determined enthalpy of interaction (DHint(exp)). The calcula-
tions were done by our computer program utilizing an iterative
non-linear least square regression method to minimize the value
of
P
(DHint(exp)DHint(calc))2 and are given in Table 2.
The values of free energy of inclusion (DGo) and entropy of
inclusion (DSo) were calculated from the following equations:
DGo ¼RT lnK ð5Þ
DSo ¼ ðDHoDGoÞ=T ð6Þ
The table shows that the inclusion of drug is exothermic process
(DHo is negative) while entropy of reaction is positive in all these
cases leading to values of Gibbs free energy (DGo) between
18.33 and 20.7 kJ/mol. The favorable enthalpy and entropy
changes indicate proper ﬁt of artesunate into the CD cavity.
Table 2 shows that the numerical value of DHo is the highest in
As–Me-b-CD complex. The enthalpic gain is obtained predomi-
nantly through van der Waals interaction of methyl group
introduced in M-bCD. However, this decrease in DHo in case of
Me-b-CD is more or less compensated by lesser positive entropy
change (Table 2). In the case of HP-b-CD, the hydroxyl groups
make the CD cavity partially hydrophilic and the complexation
reaction between HP-b-CD and artesunate is less enthalpically
driven but are accompanied by a more positive entropy change.nd HP-b-CD as well as in the presence of PEG at pH 6.8 in
l) DGo (kJ/mol) DSo (J/mol/K)
.005 –18.3370.008 29.7870.005
.006 –19.3970.007 27.0770.006
.006 –20.0770.006 25.9770.006
.013 –19.8970.008 26.117 0.013
R. Chadha et al. / Results in Pharma Sciences 1 (2011) 38–4846The magnitudes of stability constant (K) reveals that host–
guest afﬁnity is found to be maximum (2410 M1) for artesunate
Me-b-CD complex. Interestingly, it compares well with K value for
ternary complexes (As–b-CD in the presence of PEG), which have
nearly the same magnitude (2250 M1). This shows that b-CD in
the presence of PEG has approximately the same complexation
efﬁciency as Me-b-CD alone has towards artesunate. Polymer
establishes different interactions with CD and drug molecules
such as hydrophobic bonds, Van der Waals dispersion forces or
hydrogen bonds. Besides this, strong interaction between CD and
artesunate is reﬂected in less positive entropy in the presence ofFig. 11. Dissolution studies in artesunate in binary and ternary systems.
Fig. 12. RMSD, Coulombic, van der Waals and H-bond interactionPEG (Table 2). Addition of PEG to As–b-CD binary complex
resulted in marked enhancement in the complexation and solu-
bilizing efﬁciencies of b-CD and this approach seems useful for
improving the performance of b-CD.
3.8. Dissolution studies
All the binary systems show signiﬁcantly improved dissolution
rate as compared to the pure drug. It is also clear that release rate
is fastest for Me-b-CD followed by HP-b-CD and b-CD complexes.
In the case of ternary system, dissolution is fastest in lyophilized
complexes as to PM, KN and CoE systems. The increase in
dissolution rate in lyophilized binary and ternary complexes
may be due to the true inclusion as well as due to the high
energy amorphous state of lyophilized products (Fig. 11). In the
presence of hydrophilic polymers a smaller amount of CD is
used to obtain the desired dissolution proﬁle. Signiﬁcant
enhancements in dissolution rate of freeze dried product of
ternary complex may be attributed to an increase in solubility
upon complexation of b-CD as well as due to polymer. Thus,
addition of hydrophilic polymers could be a strategy for improv-
ing the usefulness of CDs. The lyophilized complex with the
highest dissolution rate is most suitable product for the animal
studies.
3.9. Molecular modeling studies
During the trajectory analysis, it was seen that the b-CD–
artesunate complex retained its structure and was stable during the
entire time period of the simulation. The average root-mean-squares mapped over a 5 ns MD trajectory of the As–b-CD complex.
R. Chadha et al. / Results in Pharma Sciences 1 (2011) 38–48 47deviation (RMSD) for the complex over the entire trajectory of
5 ns was computed as 1.33, while that of the ﬁnal frame was 1.56
(Fig. 12). This shows that the b-CD–artesunate complex does not
separate out and remains steady throughout the time period of
simulation, which is acceptable in simulations. The interaction
energies (Coulombic, van der Waals) between b-CD andTable 3
Interaction energies (Coulombic, van der Waals), H-bond counts and RMSD (w.r.t.
frame zero in simulation) computed over the MD trajectory of the BCD–artesunate
complex.
Sl.
no.
Structure Interaction
energies
(kcal/mol)
Binding
energies
(kcal/mol)
1. Max. total energy – 37.22
2. Min. total energy – 40.72
3. Mean. total energy – 4.89
4. Max. Coulombic energy 20.3 31.0
5. Min. Coulombic energy 1.3 48.3
6. Mean Coulombic energy 39.0 7.9
7. Max. van der Waals energy 30.9 33.3
8. Min. van der Waals energy 19.8 21.7
9. Mean. van der Waals energy 37.3 3.1
10. Max. no. of H bonds 5 –
11. Min. no of H bonds 0 –
12. Average no. of H bonds 2 –
13. Max. RMSD 1.338 –
14. Min. RMSD 2.171 –
Energy values in kcal/mol.
Fig. 13. The space-ﬁll model of artesunate (guest) and b-cyclodextrin (host)
depicting the intermolecular interactions.
Table 4
Antimalarial activity of binary and ternary lyophilized complexes o
Sl. no. Groups Treatment
1 Control group 0.5% CMC solution
2 Standard group Artesunate (6 mg/kg)
3 Test group 1 Asb-CD (6 mg/kg of artesun
4 Test group 2 As–HP-b-CD (6 mg/kg of arte
5 Test group 3 As–Me-b-CD (6 mg/kg of arte
6 Test group 4 As–b-CD–PEG (6 mg/kg of art
t¼no. of days.
n¼no. of animals per group.
PI¼post inoculation.
As–b-CD¼artesunate–b-cyclodextrin complexes.
As–Me-b-CD¼artesunate–methyl-b-cyclodextrin complexes.
As–HP-b-CD¼artesunate–hydroxypropyl-b-cyclodextrin complexes
As–b-CD–PEG¼artesunate–b-cyclodextrin–PEG complexes.
n Values were expressed as mean7SD (standard deviation).artesunate were computed to be 20.31 and 30.93 kcal/mol
(Table 3) and are further used for calculating the binding energy
for the entire trajectory:
DGbinding ¼DGcomplexðDGhostDGguestÞ
The mean binding energy computed for b-CD–artesunate com-
plex is 4.89 kcal/mol (20.46 kJ/mol), which is close to the
experimentally determined values. The visual inspection of the
complex presents that on an average there are two H-bond
interactions between b-CD and artesunate. The ﬁrst H-bond
occurs between proton-o (Fig. 8a) and the primary OH group of
b-CD, while the second is seen between the carboxlyate group
and secondary OH groups (varying in between the 20-OH and 30-
OH groups) of the b-CD. The artesunate core is snugly ﬁtted into
the host cavity exhibiting an excellent interaction with the pyran
rings of the sugar residues (Fig. 13).
3.10. In vivo antimalarial activity of artesunate and its binary
and ternary inclusion complexes
The effectiveness of the binary and ternary complexes was
conﬁrmed by performing in vivo antimalarial activity against
P. berghei infection. Suspensions containing artesunate, binary
and ternary inclusion complexes were tested with respect to
parasitemia progression and survival period. It is clear from the
Table 4 that mice treated with artesunate dose (Standard Group)
signiﬁcantly prolonged their survival period (day 15–18) com-
pared to control (day 9), but is insufﬁcient to prevent the
mortality. Test Group 1, Test Group 2 and Test Group 4 treated
mice died between 15–25 days, 20–26 and 27–30 days,Fig. 14. Antimalarial activity of Me-b-CD lyophilized complexes of artesunate in P.
berghei infected mice ‘‘(n¼6)’’ as compared to drug.
f artesunate in P. berghei infected mice.
Mean % parasitemia n
on day 8th PI
% Survivality
(n¼6, t¼30 days)
49.23712.34 0
8.4873.21 16.7
ate) 6.2576.82 50
sunate ) 4.2779.43 67.7
sunate ) 0.00270.0016 100
esunate) 1.02571.04 83.3
.
R. Chadha et al. / Results in Pharma Sciences 1 (2011) 38–4848respectively, whereas Test Group 3 (Ternary lyophilized system)
resulted in a 100% survival of infected mice even after 30 days.
Survival rate of the infected mice increases from 16.7% to 50%,
67%, 83.3% for standard group and binary complexes of artesunate
with b-CD, HP-b-CD and ternary complexes of b-CD, respectively.
Binary Me-b-CD lyophilized suspensions are found to be more
effective against P. bergheimalaria with 0% mortality. Signiﬁcantly
less (Po0.001) mean percent parasitemia was observed in the
Test Group 3 (0.00270.0016) compared to all test groups. ANOVA
have also shown signiﬁcant (Po0.05) antimalarial activity of all
binary and ternary complexes as to artesunate (Fig. 14).4. Conclusion
The mean binding energy computed by molecular modeling
for b-CD–artesunate complex is correlated well with the experi-
mentally determined values. The ternary systems clearly signify
superiority over binary complexes in terms of solubility and
reduction in the formulation bulk. PEG was found to be the most
suitable auxiliary substance in terms of superior complexation
efﬁciency and stability constant. Higher stability constant values
in the presence of PEG suggest a signiﬁcant improvement in the
complexation efﬁciency between artesunate and b-CD. This is
supported by the in vitro dissolution rate, which was found to be
maximum for Me-b-CD lyophilized complexes. Enhanced in vivo
antimalarial activity and protective efﬁcacy against P. berghei
infection was observed for the complexes. However, increment is
more in the presence of PEG. Best survival rate was observed for
binary complexes with Me-b-CD, which is comparable to the
ternary complexes of b-CD in the presence of PEG. Thus, encap-
sulation of artesunate by cyclodextrins in the presence of PEG is a
good alternative to enhance the bioavailability of the drug as well
as to enhance its antimalarial activity.Acknowledgment
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